All News

16 June 2007

Actemra: Roche’s novel rheumatoid arthritis drug shows substantial benefits for patients in OPTION studyAntibodies

15 June 2007

Genmab initiates ofatumumab frontline NHL studyAntibodies

15 June 2007

Algeta demonstrates targeted cancer-killing potential of novel alpha particle linked antibodies in leading medical journal BloodAntibodies

15 June 2007

Human Genome Sciences reports that a Phase 2 study of LymphoStat-B(R) showed significant reductions in disease activity in patients with active systemic lupus erythematosusAntibodies

15 June 2007

CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid ArthritisAntibodies

15 June 2007

Anti-TNF golimumab continues to show promise in Phase II rheumatoid arthritis studyAntibodies

14 June 2007

ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULARAntibodies

13 June 2007

Favrille Acquires Anti-CD20 Monoclonal Antibodies from DiversaAntibodies

12 June 2007

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin’s Lymphoma Appears Safe and Active in a Phase I/II StudyAntibodies

12 June 2007

NEOPHARM, Inc. Signs Exclusive License Agreement for the Use of CINTREDEKIN BESUDOTOX (IL13-PE38QQR) for the Treatment of Pulmonary Fibrosis and AsthmaAntibodies

12 June 2007

Viventia Biotech initiates patient treatment for Phase I trial of VB6-845 anti-cancer antibodyAntibodies

9 June 2007

Regeneron submits biologics license application To US FDA for IL-1 Tap (Rilonacept) for treatment of CAPSAntibodies

8 June 2007

Abbott’s HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn’s DiseaseAntibodies

8 June 2007

Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn’s DiseaseAntibodies

7 June 2007

Abbott and Caprion Extend Partnership to Discover Antibody Targets for CancerAntibodies

7 June 2007

Actemra: New data confirms significant improvement of disease signs and symptoms in patients with rheumatoid arthritisAntibodies

6 June 2007

Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCOAntibodies

6 June 2007

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer TherapyAntibodies

6 June 2007

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy IpilimumabAntibodies

5 June 2007

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic LeukemiaAntibodies

5 June 2007

Investigational cancer drug Pertuzumab shows promising results in advanced breast cancer when combined with HerceptinAntibodies

4 June 2007

Genmab’s HuMax-EGFr shows broad potential in cancer treatmentAntibodies

4 June 2007

Genentech Provides Update on Pipeline Agents at The American Society of Clinical Oncology MeetingAntibodies

4 June 2007

Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer SaysAntibodies

3 June 2007

Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney CancerAntibodies

3 June 2007

Results of VEGF trap (aflibercept) highlighted at ASCO 2007 annual meetingAntibodies

1 June 2007

Peregrine Pharmaceuticals Enters Into Development Collaboration with Dios TherapeuticsAntibodies

1 June 2007

Medarex Announces Collaborative Research Agreement with Mitsubishi PharmaAntibodies

31 May 2007

Human Genome Sciences and GlaxoSmithKline initiate second phase 3 clinical trial of LymphoStat-B(R) in systemic lupus erythematosusAntibodies

31 May 2007

BioWa and Takeda announce licensing of BioWa’s POTELLIGENT(R) technology for use in antibody research and developmentAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

B7-H4 Targeted Antibody Therapy Pipeline Review

Report Package: Bispecific Antibodies

Aflibercept (Eylea) Biosimilars Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

5T4-Targeted Immunotherapy Candidates Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TSLP Pipeline Review